ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Myriad Genetics (MYGN)
Myriad Genetics stock price today, ATLAS forecast and fair value
Healthcare · Diagnostics & Research · NASDAQ
$6.29▲ +4.49%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Myriad Genetics in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Myriad Genetics
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Myriad Genetics a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $5.00 and $7.26; in 9 out of 10, between $3.60 and $10.10. Estimated annual volatility is 120%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $434M
- 52-week high
- $8.38
- 52-week low
- $2.74
- Revenue (12 months)
- $807M
- Revenue growth (YoY)
- -1.6%
- Gross margin
- 69.9%
- Operating margin
- -8.2%
- Net margin
- -44.4%
- Return on equity
- -32.5%
- Free cash flow (12 months)
- $18.2M
- Beta
- 1.68
What this means
ATLAS does not publish a fair value for MYGN right now, but it does show its odds of rising: somewhat worse than a coin flip.
Over the last 52 weeks MYGN has traded between $2.74 and $8.38. Today it is 24.9% below that high and 130% above its low.
On the business: revenue fell 1.6% year over year; net margin is 44.4%.
Its beta is 1.68: it tends to move more than the market, both up and down.
About the company
Myriad Genetics Inc. is a molecular diagnostics and precision medicine company that develops genetic tests to support disease risk assessment, diagnosis, and treatment decisions.
Want to see everything about Myriad Genetics?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Myriad Genetics do?
Myriad Genetics Inc. is a molecular diagnostics and precision medicine company that develops genetic tests to support disease risk assessment, diagnosis, and treatment decisions.
What is the chance MYGN goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, MYGN ends the month between $5.00 and $7.26.
How big is Myriad Genetics and what is its P/E ratio?
Myriad Genetics's market capitalization is $434M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is MYGN?
ATLAS estimates annual volatility at 120%. In a typical month, half of the outcomes end between $5.00 and $7.26.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer